Single Dosing Clinical Trial of HL151

Inclusion criteria

• Healthy male volunteer in the age of 19-45
• Body weight≥50kg and BMI 18~29 kg/m2
• Subject who sign on an informed consent form willingly

Exclusion criteria

• Subject with serious active cardiovascular, respiratory, hepatologic, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease
• Subject with acute disease within 28 days prior to study medication dosing
• Subject with known for history of disease which affect on the absorption, distribution, metabolism, excretion of drug
• Subject with clinically significant chronic disease
• Positive on the test of HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL
• Use of any prescription medication within 14 days prior to study medication dosing
• Use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing
• Subject with clinically significant allergic disease
• Subject with known for hypersensitivity reaction to bepotastine
• Subject with any of the following conditions in laboratory test

• AST/ALT > UNL (upper normal limit) x 2
• Total bilirubin > UNL x 2
• Renal failure with CLcr < 50mL/min calculated on Cockcroft-Gault [Cockcroft-Gault GFR = (140-age) * (Wt in kg) / (72 *Cr)]
• SBP<100mmHg or ≥160mmHg, DBP<60mmHg or ≥100mmHg
• QTc>440msec on ECG
• Serum potassium < 3.5 mEq/L or > 5.5 mEq/L
• Immunological incompetence, immune deficiency or taking immunosuppressants
• Subject who cannot take standard meal
• Subject with whole blood donation within 60days, component blood donation within 20days prior to study medication dosing
• Subject with blood transfusion within 30days prior to study medication dosing
• Participation in any clinical investigation within 90days prior to study medication dosing
• Continued excessive use of caffeine (caffeine >five cups/day), alcohol(alcohol>30g/day) and severe heavy smoker(cigarette >10 cigarettes per day)
• Subject with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator
• Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within 30days prior to study medication dosing
• Subject who are not using adequate means of contraception
• Subject with genetic problems such as galactose intolerance, Lapp Lactase Deficiency or glucose-galactose malabsorption
• Subject with history of drug abuse or drug addiction